Colucci Philippe, Yue Corinne Seng, Ducharme Murray, Benvenga Salvatore
Principal Scientist, Learn and Confirm Inc.
Principal Scientist, Learn and Confirm Inc. and PhD Candidate, Faculty of Pharmacy, University of Montreal.
Eur Endocrinol. 2013 Mar;9(1):40-47. doi: 10.17925/EE.2013.09.01.40. Epub 2013 Mar 15.
Thyroxine hormone has been recognised since the early part of the nineteenth century and levothyroxine has been available since the mid-nineteenth century as a replacement for deficient thyroid hormones. While levothyroxine remains the staple treatment for hypothyroidism even to this day, its optimal use can be challenging. As is often the case with older drugs, the pharmacokinetics of levothyroxine is often under-appreciated or misunderstood and many factors influence the optimal dosing of levothyroxine. This article will review the pharmacokinetics of levothyroxine in the treatment of hypothyroidism and highlight major concepts that should aid both clinicians and researchers.
自19世纪初以来,甲状腺素就已为人所知,自19世纪中叶起,左甲状腺素就已作为甲状腺激素缺乏的替代药物上市。即使在今天,左甲状腺素仍然是治疗甲状腺功能减退的主要药物,但其最佳使用可能具有挑战性。与许多老药一样,左甲状腺素的药代动力学常常未得到充分认识或被误解,许多因素会影响左甲状腺素的最佳剂量。本文将综述左甲状腺素治疗甲状腺功能减退的药代动力学,并强调有助于临床医生和研究人员的主要概念。